Shephard Mpofu
ACELYRIN Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Shephard Mpofu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:39 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT05905783 · Hidradenitis Suppurativa Study of IzokibepACELYRIN Inc. · terminated · Hidradenitis Suppurativa · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:39 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:39 UTC. The ranking covers the 200 most relevant of 22 PubMed records, and a shared surname and initials can bring in a namesake. All 22 on PubMed
- Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.N Engl J Med · 2015826 citationsRCR 29.8
- 688 citationsRCR 24.7
- 613 citationsRCR 22.3
- Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.Ann Rheum Dis · 2018262 citationsRCR 12.5
- Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.Ann Rheum Dis · 2013237 citationsRCR 7.0
- 221 citationsRCR 12.8
- Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study.Ann Rheum Dis · 2017206 citationsRCR 8.7
- Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).Arthritis Res Ther · 2018143 citationsRCR 7.0
- Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.Rheumatology (Oxford) · 2017120 citationsRCR 4.7
- 83 citationsRCR 2.4